Aim: Anticoagulants are underused in older patients with atrial fibrillation (AF). Scoring systems, such as CHA 2 DS 2 -VASc and HAS-BLED, are recommended to guide clinicians in anticoagulation decisions, but patients' frailty might be an underrecognized factor. We investigated the association between the Clinical Frailty Scale (CFS) and community anticoagulant prescribing habits in patients aged ≥75 years with AF admitted acutely to hospital.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia in older people, and its prevalence increases with age. 1, 2 It is a risk factor for ischemic stroke, and is a powerful predictor of disability, dementia and death because of the increased severity of cardioembolic strokes compared with other stroke etiologies. 2 Cardioembolic strokes constitute a disproportionate burden of the total cost of stroke, with a twofold increase in median total healthcare costs compared with non-AF stroke. 3 As the population becomes older, the number of individuals with AF is set to increase, with cardioembolic stroke imposing a greater burden on patients, families and healthcare resources. 1, 4 Anticoagulants are the only licensed medication to reduce the risk of stroke, 5 but because of the perceived increased risk of complications, 6, 7 lower rates of anticoagulant use is seen, especially in older patients, with up to half not being anticoagulated. 8, 9 Frailty is defined as a state of vulnerability to adverse outcomes from stressors, 7 and it is recognized that frail individuals might be more susceptible to medication side-effects, 10 including those from anticoagulants. Clinical trials rarely include frail patients, therefore, 12 (which assigns 1 point to uncontrolled hypertension >160 mmHg systolic (H), abnormal renal or liver function (A), previous stroke (S), bleeding history or predisposition (B), labile international normalized ratio [INR] or time in therapeutic range <60% (L), age >65 years (E), use of antiplatelet/ anticoagulation that might increase the risk of bleeding or alcohol use defined as >8 drinks/week (D)). Guiding clinicians when weighing up the risk of stroke against the risk of bleeding, 13 guidelines do not provide specific advice on anticoagulation decisions for frail older people who are more susceptible to adverse outcomes. 14, 15 The present study investigated the association between clinical frailty, as measured by the nine-point Clinical Frailty Scale (CFS) 16 ( Fig. 1) , and community anticoagulant prescribing habits for patients aged 75 years and over, admitted acutely to hospital. An understanding of the relationship between clinical frailty and community prescribing of anticoagulants, independently of recognized decision aid tools, such as CHA 2 DS 2 -VASc and HAS-BLED, might help elucidate the importance of the frailty syndrome in AF, as well as aiding the development of future clinical decisionmaking tools that are more appropriate for this vulnerable population.
Method

Data collection
We carried out a retrospective observational study in a 1000-bed teaching hospital in the UK, between 1 January and 31 March 2014. Inclusion criteria were age ≥75 years, admission under a general medical team, a history of AF and a frailty score documented on admission. In our center, the CFS is routinely carried out in all non-elective admissions aged 75 years or more. 17 The CFS aims to capture the pre-admission, or baseline, frailty status and is calculated within 72 h of admission by a clinician and recorded in the patient medical records. Patients were divided into two groups:
"non-frail" (CFS scores 1-4) and "frail" (CFS scores 5-8). Data including patient age, sex, admission and discharge diagnosis, anticoagulation status, CHA 2 DS 2 -VASc, HAS-BLED, and frailty scores were retrospectively collected from discharge letters.
The present study was part of a Service Evaluation Audit registered with our center's Safety and Quality Support Department (project register number 3962). Formal confirmation was received that approval from the ethics committee was not required.
Statistical analysis
Data was analyzed using R (version 3.1.2; R foundation for statistical computing, Vienna, Austria). A P-value <0.05 was considered statistically significant throughout data analysis. Initially bivariable comparisons for continuous data between anticoagulated and non-anticoagulated groups were tested for normality using Shapiro-Wilk testing, with subsequent analysis using the Student's t-test or Mann-Whitney U-test for parametric and nonparametric data, respectively. Categorical data was analyzed between cohorts using the χ 2 -test. The multivariable logistic regression analysis included the following predictors of anticoagulation prescription: frailty, age, sex, and the individual components of the CHA 2 DS 2 -VASc and HAS-BLED scores, rather than the cumulative scores, to avoid duplication. Because of the overlap in hypertension, which has different definitions between the two scoring systems, we included hypertension as per the CHA 2 DS 2 -VASc score in the multivariable analysis.
Results
A total of 419 patients with known AF were included in the study. Of these, 215 were not anticoagulated (51.3%) on admission and 204 (48.7%) were anticoagulated. The use of warfarin (94.1%) heavily outnumbered both dalteparin (0.9%) and direct oral anticoagulantsdabigatran 4.1%, rivaroxaban 0.9% and apixaban 0%. In the frail cohort, six individuals were taking direct oral anticoagulants compared with five in the non-frail group. The non-anticoagulated group were older (median age 87 years, [interquartile range (IQR Q 3 -Q 1 ) 7] vs 83 years [IQR 6], P < 0.001) and had a higher prevalence of frailty (81.4% vs 52.5%, P < 0.001). Individuals admitted not taking anticoagulants had lower CHA 2 DS 2 -VASc scores (median 4 [IQR 2] vs 5 [IQR 2], P = 0.01) compared with the anticoagulated group, but there were no significant differences in the HAS-BLED scores between the two groups (P = 0.07; Table 1 ).
As clinical frailty increases, there are fewer anticoagulated individuals per CFS (Fig. 2) . For example, at CFS 3 and 4, between 70 and 73% were taking anticoagulants compared with CFS 7 and 8, where the proportion of anticoagulated individuals had dropped to 29% and 7%, respectively. However, the same pattern was not seen with changes in the CHA 2 DS 2 -VASc or HAS-BLED scores. The present results show that having had a previous stroke or TIA meant that individuals were more likely to be taking anticoagulants (P = 0.01), and a history of prior bleeding or predisposition to bleeding meant that individuals were significantly less likely to be taking anticoagulants (P = 0.001). The presence of other risk factors for stroke or bleeding as per the components of CHA 2 DS 2 -VASc and HAS-BLED scores did not differ between the anticoagulated and non-anticoagulated groups (all P > 0.05; Table 1 ). Multivariable analysis of frailty, age and sex along with the components of the CHA 2 DS 2 -VASc and HAS-BLED scores showed that individuals are more likely not to be taking anticoagulants at admission, if they are older, frailer and are felt to be at risk of bleeding. However, having had a previous stroke or TIA, or having a history of congestive cardiac failure were associated with being prescribed anticoagulants ( Table 2) .
Frailty was the strongest independent predictor of not being on anticoagulants at admission compared with age and bleeding risk (OR 0.77, 95% CI 0.70-0.85, P < 0.001), emphasizing that frail individuals are 23% less likely to be anticoagulated on admission to hospital.
Discussion
The present study explored the association between clinical frailty and community anticoagulation prescription habits in patients aged over 75 years admitted acutely to hospital. Nearly half the patients aged over 75 years in the present study were not taking anticoagulants, with frailty, age and bleeding risk emerging as independent predictors of non-anticoagulation. Multivariable analysis suggested that frailty was the strongest predictor for not being on anticoagulants at admission, even more so than bleeding risk. This shows that despite explicit frailty measurements not being routinely carried out in the community, a clinical impression of an individual as being frail is negatively associated with anticoagulation prescription.
The present results highlight the important role frailty plays in making anticoagulation decisions, and the low rates of anticoagulation observed in this study highlight that making such decisions for frail older individuals is challenging. Previous studies reported that clinician reluctance to prescribe anticoagulants, because of the difficulty in choosing between stroke and bleeding risk, is a major reason for undertreatment, suggesting that Figure 2 The number and proportion of individuals not taking anticoagulants (black) compared with those taking anticoagulants (white), when separated by clinical frailty scale, CHA 2 DS 2 -VASc and HAS-BLED scores. CFS, Clinical Frailty Scale more help and guidance is required. [18] [19] [20] However, specific geriatric characteristics that would allow safer prescription of anticoagulation have not been determined, and existing guidelines are drawn from results of those with greater physiological reserve and as such are less likely to suffer adverse outcomes. 10 This highlights the need for safer and more reliable methods of assessing the risks and benefits of anticoagulation in frail individuals, including a greater understanding of the implications of frailty in such decisions. In large epidemiological studies, the frailty phenotype has been validated as a predictor of shortand long-term adverse outcomes, including death, 21, 22 and the CFS has been shown to have accuracy in predicting in-hospital adverse outcomes. 17 Because frail individuals develop numerous deficits across multiple domains of disease, relying on rigid scoring systems, such as CHA 2 DS 2 -VASc and HAS-BLED, which contain overlapping risk factors for both stroke risk and bleeding risk, might be less applicable in frail cohorts.
The present study had some limitations. Being a singlesite study with a relatively small sample size of individuals admitted acutely to hospital, the individuals in the study might not be representative of the broader population. By nature of being a retrospective study, data collection might be limited by the record keeping, though the effects of this are limited by excluding patients without discharge summaries or recorded frailty scores, which includes those who died in hospital.
Safer and more reliable methods of assessing the risks and benefits of anticoagulation in the frail older population would be useful in clinical practice. Frailty scores are not routinely measured in primary or secondary care, yet they might offer more flexibility and judgement to the clinician to make personalized, holistic decisions. In the present study, increasing clinical frailty was associated with a lower proportion of individuals on anticoagulants, which suggests that clinicians already have an inherent idea of the concept of frailty and increased adverse outcomes. This is further supported by previous studies that showed measured frailty scales correlated well with a clinician's initial global assessment of frailty. 23 Because of the complexity of treatment in the older population, we propose that additional information gained from explicit frailty measurements might translate into clearer decision-making about anticoagulation. Further work is required to determine whether such assessments of frailty, and their role in determining anticoagulant prescribing, affect clinical outcomes. 
